Global Patient Monitoring Device Market Estimated to Generate a Revenue of $56,376.2 Million By 2028, Growing at a CAGR of 6.0% from 2021-2028 – Exclusive Report [266 Pages] By Research Dive
August 09, 2021 09:00 ET
|
Research Dive
New York, USA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- The global patient monitoring device market is expected to generate a revenue of $56,376.2 million by 2028, growing at a healthy CAGR of 6.0% during...
Global Computer Aided Drug Discovery Market to Witness Significant Rise in Revenue of $5,427.2 Billion in the Forecast Period, 2019-2026 - Exclusive Report By Reasearch Dive
July 12, 2021 09:34 ET
|
Research Dive
New York, USA, July 12, 2021 (GLOBE NEWSWIRE) -- A recent report by Research Dive stated the impact of the COVID-19 virus on the global computer aided drug discovery market. According to the report,...
Expressing Gratitude to Respiratory Therapy Professionals
June 04, 2021 09:38 ET
|
American Association for Respiratory Care - Irving, TX
Irving, Texas, June 04, 2021 (GLOBE NEWSWIRE) -- Respiratory disease is nothing new. Since the days of 1918 Flu, through pulmonary tuberculosis, SARS and H1N1, and even Katrina, respiratory therapy...
Teleflex Signs Definitive Agreement to Sell Certain Respiratory Assets and Reaffirms Adjusted EPS Guidance
May 18, 2021 06:30 ET
|
Teleflex Incorporated
Total consideration is $286 million, reduced by $12 million of working capital to be retained by TeleflexAssets to be divested generated $139M in 2020 revenue, with 2021 growth expected to be...
Anesthesia & Respiratory Devices Market Value Predicted To Reach US$ 43.7 Billion By 2027: Acumen Research And Consulting
March 31, 2021 12:24 ET
|
Acumen Research and Consulting
LOS ANGELES, March 31, 2021 (GLOBE NEWSWIRE) -- The Global Anesthesia & Respiratory Devices Market is expected to grow at a CAGR of around 6.5% from 2020 to 2027 and reach the market value of...
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
November 19, 2020 16:30 ET
|
Novartis International AG
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other...
Vitalograph Launch Powerful New In2itive e-Diary for Global Clinical Trials
October 14, 2020 09:00 ET
|
Vitalograph
Next generation eCOA device with integrated respiratory assessment Vitalograph are delighted to announce that their most powerful ever In2itive...
Grey Cloak Tech Inc. Launches Customer Relationship Management (CRM) Program to Increase Sales and Retention
October 08, 2020 08:30 ET
|
Grey Cloak Tech Inc.
LAS VEGAS, Oct. 08, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Grey Cloak Tech Inc. (OTC: GRCK – soon to be Healthy Extracts Inc. pending a corporate name change), a company engaged in proprietary...
Grey Cloak Tech Inc. Introduces ‘Clinical IMMUNE™’ to Combat Respiratory Symptoms
October 06, 2020 08:30 ET
|
Grey Cloak Tech Inc.
LAS VEGAS, Oct. 06, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Grey Cloak Tech Inc. (OTC: GRCK – name change pending to Healthy Extracts Inc.), today announces that its BergaMet NA subsidiary has...
Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
September 07, 2020 01:15 ET
|
Novartis International AG
High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair...